论文部分内容阅读
目的:观察熄风通脑胶囊联合常规疗法治疗急性脑梗死的临床疗效。方法:将200例急性脑梗死患者随机分为治疗组和对照组。2组患者均给予脑梗死常规处理,治疗组同时加用熄风通脑胶囊口服。治疗前后评价患者的美国国立卫生研究院卒中量表(NIHSS)评分、功能独立性评估量表(FIM)评分,检测血浆C-反应蛋白(CRP)含量以及记录药物不良反应。结果:临床疗效总有效率治疗组为91.00%,对照组为75.00%,2组比较,差异有统计学意义(P<0.05)。治疗后1月,2组NIHSS评分、CRP含量均较入院时降低(P<0.05),FIM评分较入院时增高(P<0.05);与对照组治疗后比较,治疗组NIHSS评分、CRP含量均低于对照组(P<0.05),FIM评分高于对照组(P<0.05)。2组患者均未发生严重的药物不良反应。结论:熄风通脑胶囊联合常规疗法对急性脑梗死患者疗效显著,安全且无毒副作用。
Objective: To observe the clinical efficacy of Xifengtongnao Capsule combined with conventional therapy in the treatment of acute cerebral infarction. Methods: 200 patients with acute cerebral infarction were randomly divided into treatment group and control group. Both groups were given conventional treatment of cerebral infarction, the treatment group also added Xifengtongnao capsule oral. The NIHSS score, functional independence assessment scale (FIM) score, plasma C-reactive protein (CRP) level, and adverse drug reaction were recorded before and after treatment. Results: The total effective rate of the treatment group was 91.00% in the control group and 75.00% in the control group. There was significant difference between the two groups (P <0.05). At 1 month after treatment, NIHSS score and CRP content in both groups were lower than those at admission (P <0.05), and FIM scores were higher than those at admission (P <0.05). Compared with the control group, NIHSS score and CRP level Lower than the control group (P <0.05), FIM score higher than the control group (P <0.05). Two groups of patients did not occur serious adverse drug reactions. Conclusion: Xifengtongnao capsule combined with conventional therapies has significant curative effect on patients with acute cerebral infarction, with safe and non-toxic side effects.